IGNITE Canada: Developing Pod System V15000 with Smart Screen Upgrade

Sep.20.2024
IGNITE Canada: Developing Pod System V15000 with Smart Screen Upgrade
Canadian brand IGNITE drew attention at the Dortmund tobacco exhibition with its innovative products from September 19-21.

At the Dortmund Tobacco Expo from September 19 to 21, the Canadian brand IGNITE attracted a lot of attention with its innovative products. Lisa Kabatsky, Global Operations Manager of IGNITE International Brands, told 2Firsts that at this exhibition, IGNITE showcased two disposable products, v8000 and v15000. The v8000 was launched last year, while the v15000 was just released a few months ago and had not yet been introduced to the German market.

IGNITE Canada: Developing Pod System V15000 with Smart Screen Upgrade

Lisa Kabatsky, Global Operations Manager of IGNITE International Brand, | Image source: 2Firsts

 

IGNITE Canada: Developing Pod System V15000 with Smart Screen Upgrade

IGNITE has released disposable products v8000 and v15000. | Image source: 2Firsts.

 

IGNITE Canada: Developing Pod System V15000 with Smart Screen Upgrade

IGNITEdisposable product v8000 | Image source: 2Firsts

 

Due to strict regulations in the local market, IGNITE is focusing on promoting low-nicotine products in the German market, while simultaneously developing switchable products that comply with regulations. Lisa Kabatsky stated that there is high demand for ice-flavored products in the German market, with no strong preference for other flavors and no noticeable trends.

 

IGNITE has expressed their views on the future trends of e-cigarettes to 2Firsts. Lisa Kabatsky believes that smart e-cigarettes are the way of the future, with the company upgrading their v15000 model and planning to equip it with a smart side screen to cater to the market's demand for smart products. Additionally, Lisa Kabatsky stated that IGNITE is also producing n-in-1 and 2+10 products, expected to be launched in the UK and EU regions, further expanding the company's market presence.

 

Lisa Kabatsky criticizes the regulatory policies issued by the United States FDA, stating that they have a negative impact on industry innovation and corporate development.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

2Firsts Exclusive Analysis | RLX Q1 Revenue Rises 96.2%, International Business Points to a More Integrated Global Strategy
2Firsts Exclusive Analysis | RLX Q1 Revenue Rises 96.2%, International Business Points to a More Integrated Global Strategy
RLX Technology’s Q1 net revenues rose 96.2% year over year, with international business accounting for 72.3% of total revenue. Beyond the headline growth, the results point to deeper globalization: European operations, Nexus supply-chain integration and a broader product portfolio are becoming key signals to watch.
Special Report
May.20
FDA Commissioner Marty Makary Resigns After Opposing Trump Administration’s Flavored Vape Push
FDA Commissioner Marty Makary Resigns After Opposing Trump Administration’s Flavored Vape Push
FDA Commissioner Marty Makary resigned on May 12 after opposing the Trump administration’s push to authorize fruit-flavored vaping products, according to reporting by The New York Times. Makary reportedly objected over concerns that flavored vapes could attract young people and refused to support broader approvals.
News
May.13
Canada Faces Growing Debate as Youth Nicotine Pouch Use Reaches 34.8%
Canada Faces Growing Debate as Youth Nicotine Pouch Use Reaches 34.8%
New Canadian research shows that 34.8% of people aged 17 to 27 have tried nicotine pouches, up more than fourfold from 7.6% in 2022. The findings come as Conservative politicians, Alberta’s government and the tobacco industry push Ottawa to relax current restrictions on pouch sales.
Jun.12
WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
Ahead of World No Tobacco Day 2026, WHO released its first global report on nicotine pouches, warning that rapid market growth, youth-oriented marketing and weak regulation are converging. 2Firsts views the report as an important warning, but not a complete risk assessment, with harm-reduction questions still unresolved.
Special Report
May.17
FDA Defines Enforcement Focus for Unauthorized E-Cigarettes and Nicotine Pouches
FDA Defines Enforcement Focus for Unauthorized E-Cigarettes and Nicotine Pouches
The U.S. Food and Drug Administration issued guidance on May 8, 2026, titled “Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization.” The document describes FDA enforcement policies for certain electronic nicotine delivery system products and nicotine pouch products marketed without premarket authorization.
May.09 by 2FIRSTS.ai
FDA Renews Exposure Modification Authorization for IQOS Devices and Three HeatSticks Products
FDA Renews Exposure Modification Authorization for IQOS Devices and Three HeatSticks Products
U.S. Food and Drug Administration renewed modified risk granted orders for five IQOS products from Philip Morris Products S.A., including two IQOS system holders and chargers and three HeatSticks products. Under the renewed orders, the products may continue to be marketed with an exposure modification claim.
Apr.20 by 2FIRSTS.ai